Streetbeat News

SCPX

Scorpius Holdings, Inc.

https://www.scorpiusbiologics.com

Industry

Biotechnology

Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

Open

0.71

Mkt cap

2.1M

Volume

72K

High

0.73

P/E Ratio

N/A

52-wk high

8.11

Low

0.66

Div yield

N/A

52-wk low

0.02

Scorpius Holdings has launched Scorpius Ventures, a new business unit aimed at supporting U.S. biotech innovation. The unit will use a flexible equity-based onshoring model to provide services to promising biotech companies, aligning with the BIOSECURE Act's goals to enhance U.S. biosecurity and production capacity.

Portfolio Pulse from

November 19, 2024 | 12:45 pm

Scorpius Holdings reported its third quarter 2024 results, emphasizing strategic partnerships, cost savings, and progress towards profitability. The company is focused on enhancing its financial and operational performance.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

Scorpius Holdings has announced strategic cost-saving measures expected to save over $2 million annually. These include divesting non-core assets and optimizing operational efficiency, aiming to enhance financial position and focus on high-margin growth areas.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:44 am

In Thursday's after-market session, several health care stocks experienced significant price movements. Bionomics, Lyell Immunopharma, and Edwards Lifesciences were among the top gainers, while DexCom, Quince Therapeutics, and Universal Health Services saw notable declines. The movements were influenced by Q3 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 8:31 pm

Scorpius Holdings, Inc (NYSE American: SCPX) has been selected to join the Medical CBRN Defense Consortium, which focuses on developing medical countermeasures against CBRN threats. This partnership will allow Scorpius to contribute its expertise to advance national security technologies.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:17 pm

Scorpius Holdings, Inc. (NYSE American: SCPX) has signed a contract to provide bioanalytical services for a clinical-stage immuno-oncology company. This collaboration may lead to future GMP manufacturing opportunities, enhancing Scorpius' position in the biologics manufacturing sector.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:03 pm

Scorpius has been selected for a partnership to accelerate the development of medical countermeasures, supporting the Biomedical Advanced Research and Development Authority (BARDA).

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:44 pm

Scorpius Holdings, Inc (NYSE American: SCPX) has expanded its biologic manufacturing capabilities, resulting in a threefold revenue increase for the first half of 2024. The company raised $14.4 million to support growth and transition key clients to full-scale manufacturing.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 12:14 pm

Scorpius Holdings reported a Q2 EPS of $(26.98) and revenue of $0.8M, an increase from $0.7M year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 1:28 pm

Scorpius Holdings has announced a new pricing of a $12.5 million underwritten public offering, consisting of 12.5 million shares of common stock or pre-funded warrants. The company also has a 45-day option to purchase an additional 1.875 million shares. Additionally, Scorpius Holdings has received approval for a financial viability exception from the NYSE American.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.